13F reference period
Q2 2026
Security Snapshot
CRISPR Therapeutics AG - Common Stock (CRSP) Institutional Ownership
CUSIP: H17182108
13F Institutional Holders and Ownership History from Q1 2016 to Q3 2026
Institutions Reporting
519
Shares (Excl. Options)
76.23M
Full value: 76,233,573 · shares · 30 Jun 2026Price
$54.54
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- CRSP on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 76,233,573
- Total 13F value
- $4,158,324,848
- Portfolio coverage rank
- 0%
- Share change
- -962,290
- Value change
- -$43,311,247
- Number of holders
- 519
- Shares outstanding
- 97,024,000
- SEC-reported price per share
- $55.32
- Insider filing price
- $55.32
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- CRSP - CRISPR Therapeutics AG - Common Stock is tracked under CUSIP H17182108.
- 519 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 492 to 519 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$3.67B
Full value: $3,669,254,407 · USD · 31 Mar 2026.$4.16B
Full value: $4,158,324,848 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 519 institutions filings for Q2 2026.
Security key
H17182108
13F reference period
Q2 2026
13F holders
519
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
CRSP full holder history
CRISPR Therapeutics AG SEC filings
CRISPR Therapeutics AG company facts
CRISPR Therapeutics AG insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP H17182108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
CRSP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARK Investment Management LLC | 12% | +9.4% | $538,189,046 | +$72,622,740 | 11,313,623 | +16% | ARK Investment Management LLC | 31 Mar 2026 |
| BlackRock, Inc. | 8.3% | +20% | $435,625,269 | +$112,070,374 | 7,987,262 | +35% | BlackRock, Inc. | 30 Jun 2026 |
| ORBIS INVESTMENT MANAGEMENT LTD | 5.6% | -12% | $289,868,902 | -$35,042,948 | 5,433,344 | -11% | ORBIS INVESTMENT MANAGEMENT LTD | 30 Jun 2026 |
| Capital World Investors | 5.1% | $270,280,537 | 4,929,428 | Capital World Investors | 31 Mar 2026 | |||
| Capital International Investors | 1.2% | -89% | $62,235,477 | -$269,926,929 | 1,186,794 | -81% | Capital International Investors | 30 Jan 2026 |
As of 30 Jun 2026,
519
institutional investors reported holding
shares of
CRISPR Therapeutics AG - Common Stock (CRSP).
This represents
79%
of the company’s total
outstanding shares.
76.23M
Full value: 76,233,573 · shares · 30 Jun 202697.02M
Full value: 97,024,000 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
64%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ARK Investment Management LLC | 9.8% | 9,460,939 | -16% | 3.4% | $515,999,631 |
| BlackRock, Inc. | 8.6% | 8,348,977 | +8.7% | 0.01% | $455,353,197 |
| Orbis Allan Gray Ltd | 5.6% | 5,449,161 | -11% | 1% | $297,197,241 |
| Capital World Investors | 4.9% | 4,749,525 | +0.52% | 0.03% | $259,039,094 |
| STATE STREET CORP | 4.5% | 4,321,666 | +8.5% | 0.01% | $235,703,664 |
| GSK plc | 3.3% | 3,220,627 | 0% | 29% | $175,652,997 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6% | 2,509,915 | +5.6% | 0.01% | $136,919,043 |
| T. Rowe Price Investment Management, Inc. | 2.1% | 2,053,017 | -30% | 0.07% | $111,972,000 |
| SR One Capital Management, LP | 2.1% | 2,038,763 | 0% | 11% | $111,194,134 |
| TWO SIGMA INVESTMENTS, LP | 2% | 1,988,621 | +34% | 0.08% | $108,459,389 |
| FMR LLC | 2% | 1,908,503 | -2.4% | 0% | $104,089,735 |
| Sumitomo Mitsui Trust Group, Inc. | 1.8% | 1,720,734 | -7.2% | 0.05% | $93,848,832 |
| Amova Asset Management Americas, Inc. | 1.8% | 1,720,097 | -7.2% | 1.2% | $93,762,487 |
| EcoR1 Capital, LLC | 1.4% | 1,389,276 | 0% | 3.8% | $75,771,113 |
| UBS Group AG | 1.4% | 1,317,499 | -25% | 0.01% | $71,856,395 |
| Capital International Investors | 1.3% | 1,268,407 | +6.9% | 0.01% | $69,178,918 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.2% | 1,181,847 | +3.4% | 0% | $64,457,935 |
| BANK OF AMERICA CORP /DE/ | 1.2% | 1,155,105 | +17% | 0% | $62,999,405 |
| NEA Management Company, LLC | 1.1% | 1,058,570 | 0% | 3.6% | $57,734,408 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.1% | 1,057,837 | +1.8% | 0.01% | $57,694,430 |
| D. E. Shaw & Co., Inc. | 0.92% | 893,812 | 0.03% | $48,748,506 | |
| MORGAN STANLEY | 0.91% | 879,949 | +32% | 0% | $47,992,455 |
| NORTHERN TRUST CORP | 0.89% | 863,091 | +7.6% | 0.01% | $47,072,983 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.67% | 648,713 | +19% | 0% | $35,380,807 |
| VANGUARD FIDUCIARY TRUST CO | 0.59% | 570,040 | +5% | 0.01% | $31,089,982 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
42
Headline period
Q2 2026
Rows shown
1-25 of 42
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 2,794,809 | $154,466,503 | -$7,450,820 | $55.32 | 127 |
| 2026 Q2 | 76,233,573 | $4,158,324,848 | -$43,311,247 | $54.54 | 519 |
| 2026 Q1 | 77,168,151 | $3,669,254,407 | +$19,347,858 | $47.57 | 492 |
| 2025 Q4 | 76,493,423 | $4,012,552,808 | +$35,291,528 | $52.44 | 477 |
| 2025 Q3 | 72,232,014 | $4,681,196,062 | +$29,481,399 | $64.81 | 435 |
| 2025 Q2 | 72,314,703 | $3,517,677,257 | +$428,897,837 | $48.64 | 426 |
| 2025 Q1 | 64,129,300 | $2,183,568,653 | -$16,834,672 | $34.03 | 388 |
| 2024 Q4 | 64,443,699 | $2,536,549,693 | +$179,624,639 | $39.36 | 398 |
| 2024 Q3 | 59,826,628 | $2,811,325,020 | +$6,501,203 | $46.98 | 407 |
| 2024 Q2 | 59,510,276 | $3,214,159,736 | +$50,043,500 | $54.01 | 439 |
| 2024 Q1 | 57,288,998 | $3,904,937,558 | +$217,314,654 | $68.16 | 469 |
| 2023 Q4 | 55,520,285 | $3,475,779,179 | +$42,550,297 | $62.60 | 465 |
| 2023 Q3 | 54,993,134 | $2,496,662,136 | -$1,898,845 | $45.39 | 400 |
| 2023 Q2 | 54,718,539 | $3,071,120,295 | -$80,853,798 | $56.14 | 409 |
| 2023 Q1 | 56,199,828 | $2,540,792,585 | +$38,754,979 | $45.23 | 375 |
| 2022 Q4 | 55,494,852 | $2,255,613,450 | -$74,822,214 | $40.65 | 386 |
| 2022 Q3 | 56,683,321 | $3,701,432,142 | -$78,744,860 | $65.35 | 410 |
| 2022 Q2 | 55,502,675 | $3,344,489,851 | +$271,662,077 | $60.77 | 404 |
| 2022 Q1 | 49,481,600 | $3,107,777,604 | +$483,746,495 | $62.77 | 415 |
| 2021 Q4 | 42,884,873 | $3,253,105,466 | +$73,035,179 | $75.78 | 425 |
| 2021 Q3 | 40,405,115 | $4,522,264,525 | -$41,114,506 | $111.93 | 458 |
| 2021 Q2 | 40,533,549 | $6,560,272,742 | -$153,120,996 | $161.89 | 484 |
| 2021 Q1 | 42,643,720 | $5,195,793,257 | -$576,803,869 | $121.85 | 431 |
| 2020 Q4 | 47,170,730 | $7,222,892,447 | +$35,286,644 | $153.11 | 397 |
| 2020 Q3 | 47,858,309 | $4,002,814,216 | +$723,322,979 | $83.64 | 300 |